Company Overview of Zensun (Shanghai) Sci. &Tech. Co., Ltd.
Zensun (Shanghai) Sci. &Tech. Co., Ltd., a bio-tech pharmaceutical company, engages in the research and development of anti-tumor and anti-heart failure drugs. Its products include NEUCARDIN, a recombinant human neuregulin peptide for the treatment of heart failure; recombinant human ErbB3 fragment, a therapeutic tumor vaccine; recombinant human neuregulin-1, an anti-heart failure drug; and recombinant human ErbB3 fragment immunization, a therapeutic cancer vaccine. The company’s products in pipeline include vaccines to overcome the immuno suppression; neuregulin mutants; enzyme inhibitors; and therapeutic antibodies for small cell lung cancer. It also offers services in the areas of animal ...
No. 328 2nd Floor C Bi Bo Road
Key Executives for Zensun (Shanghai) Sci. &Tech. Co., Ltd.
Founder, Chief Executive Officer and Chief Scientist
Executive Vice President of Global Clinical Trial
Vice President and Secretary of Board
Director of Administration
Compensation as of Fiscal Year 2014.
Zensun (Shanghai) Sci. &Tech. Co., Ltd. Key Developments
SciClone Pharmaceuticals, Inc. and Zensun (Shanghai) Science & Technology Co., Ltd. Enters into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin for the China Market
May 16 13
SciClone Pharmaceuticals, Inc. announced that it has entered into an agreement with Zensun (Shanghai) Science & Technology Co., Ltd. granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Neucardin(TM), a novel, first-in-class therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure. Neucardin is a genetically engineered recombinant peptide fragment of neuregulin-1 that has been clinically shown to directly improve cardiac function, reverse ventricular remodeling and increase the survival of heart failure patients. Six Phase 2 studies with Neucardin have been conducted in China, Australia and the United States, including three Phase 2b studies in China. The China Phase 2b survival study demonstrated that Neucardin was well tolerated and showed a significant decrease in mortality and improved survival in patients with CHF. A New Drug Application (NDA) was submitted to and accepted by the China Food and Drug Administration (CFDA) in 2012.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries